EGFR and neoplasm: Blockade of EGFR with specific tyrosine kinase inhibitors (TKIs) generates dramatic tumor responses and has shown significant efficacy in the treatment of patients carrying specific mutations in the EGFR TK domain in their tumor cells1,3–5.